Sustained Release Beraprost This study looked at the addition of sustained release beraprost or placebo added to inhaled Tyvaso. United Therapeutics, the study sponsor, announced that there was no benefit found.  This will probably be the end of the road for the molecule beraprost. Many years ago the non-sustained release formulation was studied in PAH … [Read more...]

Although the progress of the implanted pump system for Remodulin has been a little like watching paint dry on the wall, we are inching closer to having this new system available for patients.  The clinical trial is now well into its eighth year.  The FDA has approved the pump and the catheter system.  United Therapeutics and Medtronic (the two companies that make the medication … [Read more...]

The PAH community is fortunate to have many treatment options.  14 medications are approved and probably more coming.  But for some patients, medications are not enough.  We have long recognized that patients with congenital heart disease (abnormal communications in their heart) who have PAH have a much better prognosis. What is Atrial Septostomy? In certain parts of the … [Read more...]

Pulmonary arterial hypertension is caused by abnormal changes in the pulmonary arteries of patients. These changes include increased thickness of the muscle layer of the pulmonary arteries and increased stiffness of the pulmonary arteries.  Over the last 25 years, 14 medications have been approved to try and treat these changes. These medications have resulted in dramatic … [Read more...]

It has been some time since I last wrote about avoiding Stem Cell Therapy.  Recently several of my patients have been suckered into this trap. Stem cells are bone marrow derived cells that have the potential to divide and become cells of any part of our body.  There is great promise in trying to understand how to develop effective treatments that use these cells.  … [Read more...]